Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premedication to prevent mannitol-induced airway narrowing in bronchiectasis
ACTRN12607000379415Phase 4Terminated
- Sponsor
- Sydney South West Area Health Service
- Start
- Aug 2007
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of sodium cromoglycate, formoterol and Bronchitol in bronchiectasis (3 arms), sponsored by Sydney South West Area Health Service. Primary endpoints: Dose of mannitol required to induce a 15% fall in FEV1 and Response dose ratio. Started Aug 2007; status: terminated.
02
Drugs
sodium cromoglycateformoterolBronchitol
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ACTRN12607000379415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000379415.